LVLU vs VERA vs CLDX vs CURV

For growth investors, Torrid Holdings Inc.

(CURV) is the stronger pick with -9. 4% revenue growth year-over-year, versus -78. 6% for Celldex Therapeutics, Inc. (CLDX). Analysts rate Vera Therapeutics, Inc. (VERA) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Vera Therapeutics, Inc.

(VERA) delivered a total return of +212. 0%, compared to -94. 8% for Lulu's Fashion Lounge Holdings, Inc. (LVLU). Over 10 years, the gap is even starker: VERA returned +212. 0% versus LVLU's -94. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Lulu's Fashion Lounge Holdings, Inc.

(LVLU) is the lower-risk stock at 0. 41β versus Celldex Therapeutics, Inc. 's 1. 73β — meaning CLDX is approximately 320% more volatile than LVLU relative to the S&P 500. On balance sheet safety, Celldex Therapeutics, Inc. (CLDX) carries a lower debt/equity ratio of 0% versus 3% for Lulu's Fashion Lounge Holdings, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Torrid Holdings Inc.

(CURV) is pulling ahead at -9. 4% versus -78. 6% for Celldex Therapeutics, Inc. (CLDX). On earnings-per-share growth, the picture is similar: Celldex Therapeutics, Inc. grew EPS -59. 2% year-over-year, compared to -176. 7% for Lulu's Fashion Lounge Holdings, Inc.. Over a 3-year CAGR, LVLU leads at -5. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Vera Therapeutics, Inc.

(VERA) is the more profitable company, earning 0. 0% net margin versus -172. 5% for Celldex Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CURV leads at 2. 1% versus -191. 6% for CLDX. At the gross margin level — before operating expenses — CLDX leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Lulu's Fashion Lounge Holdings, Inc.

(LVLU) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 41)). Celldex Therapeutics, Inc. (CLDX) carries a higher beta of 1. 73 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LVLU: -94. 8%, CLDX: -43. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (LVLU (Consumer Cyclical) and VERA (Healthcare) and CLDX (Unknown) and CURV (Consumer Cyclical)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.